Cell reportsHumansButyrophilinsReceptorsAntigenT-Cell
BTN2A1 acquisition through trogocytosis enhances Vγ9Vδ2 T cell cytotoxicity against autologous and cancer cells.
Emilien Billon, Caroline Imbert, Damien Bruyat, Pierre Grassi, Lucie Robert, Téo Fernez, Philippe Livrati, Amira Ben Amara, Marie-Sarah Rouvière, Manon Richaud, Nicolas Boucherit, Jacques A Nunès, Renaud Sabatier, Éric Lambaudie, Anne-Sophie Chrétien
Published: 202510.1016/j.celrep.2025.116387
Abstract
Butyrophilins (BTNs) are emerging as novel druggable immune targets in oncology, promoting the activation of gamma delta (γδ) T cells against cancer cells. Therapies targeting BTN3A or BTN2A1 are under development, but their regulation is poorly unde…
Preview only. Read the full abstract at the source